Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma

Clinical trial NCT00452569 · COMPLETED

Trial details

NCT number: NCT00452569
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2006-02-01
Primary completion: 2008-12-01
Enrollment: 499

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.